Dean Haubrich, PhD
President & Chief Executive Officer

In April 2009, Dr. Haubrich was appointed Interim President and CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Previously, he held the position of Interim President and Chief Executive Officer of OPDC's sister company, Otsuka America Pharmaceutical, Inc. (OAPI). He is also the Chairman of the OAPI Board of Directors.

Dr. Haubrich joined Otsuka more than three years ago as Vice President, Corporate Management for the Global Development and Commercialization Unit (GD&C) of OAPI in Princeton. He worked across the development and commercialization teams to execute a new business process which focuses on integrating commercial planning with clinical development at an early stage in drug development, the identification of clear action points in the development process, and the creation of cross-functional Project Development Teams. While leading OAPI, Dr. Haubrich implemented a new governance structure recruited top leadership talent to Otsuka, worked across OPDC and OAPI in creating a single Otsuka culture in North America, and led the transition to our permanent President and CEO for OAPI.

With 35 years of experience in the pharmaceutical industry, Dr. Dean R. Haubrich is considered an expert in drug discovery and development. Following his post-doctoral training at the National Institutes of Health, Dr. Haubrich had a successful career in the pharmaceutical industry with the Squibb Institute for Medical Research, Merck Sharp and Dohme Research Laboratories, Sterling-Winthrop Research Institute and Rhone Poulenc Rorer as both a line leader of more than 100 scientists and a project team leader in drug discovery, where he introduced several candidate compounds into clinical testing. During this phase of his career, Dr. Haubrich also established his reputation as a researcher in neurochemistry and pharmacology through more than 80 publications and abstracts. In addition, he served as a reviewer for several scientific journals, and as an adjunct professor at Princeton University, Philadelphia College of Pharmacy and Albany Medical College.

At Bristol-Myers Squibb Company, Dr. Haubrich managed teams that developed and marketed two successful drugs for the treatment of psychiatric disorders.

Dr. Haubrich has also pursued an interest in the global health area with the TB Alliance, a not for profit organization aimed at developing new drugs to treat tuberculosis.

Dr. Haubrich holds a Bachelor of Science degree with specialization in Biology and Chemistry, and Masters and Doctoral degrees in Pharmacology and Biochemistry.

William H. Carson, MD
Senior Vice President, Global Clinical Development

William H. Carson, M.D., is Senor Vice President, Global Clinical Development for Otsuka Pharmaceutical Development & Commercialization (OPDC). Dr. Carson, a psychiatrist board certified by the American Board of Psychiatry and Neurology, is based in the Princeton, NJ office of OPDC.

His primary responsibility is overseeing the global clinical development of Otsuka-discovered compounds. In addition, Dr. Carson has responsibility for Otsuka's neuroscience product development, including the direction of multinational clinical trials for aripiprazole, approving investigator-sponsored trials, authoring publications and presenting research findings.

He also leads the APEX (Aripiprazole Pediatric Efficacy Trials) Team which is conducting trials for adolescent schizophrenia and child and adolescent bipolar disorder. Additionally, he is responsible for oncology product development. Prior to joining Otsuka, he was employed as a Group Director by Bristol-Myers Squibb in Neuroscience Clinical Research and Development at the Pharmaceutical Research Institute in Wallingford, CT.

Before joining the pharmaceutical industry, Dr. Carson was an Associate Professor and Director of the Inpatient and Partial Hospital Program at the Medical University of South Carolina. He received his A.B. from Harvard College and his M.D. from Case Western Reserve University. He did his residency in Psychiatry at Tufts/New England Medical Center and a Fellowship in Affective Disorders at the Medical University of South Carolina. He is a member of the American Psychiatric Association, and the National Medical Association.

George Chao, PhD
Vice President, Biometrics

Dr. George Chao, Vice President, Biometrics, Otsuka Pharmaceutical Development & Commercialization, joined Otsuka in June 2005. Dr. Chao has more than 30 years of experience in the biostatistics and data management areas of the pharmaceutical industry and, prior to joining Otsuka, worked for Abbott Laboratories, American Critical Care, Du Pont Pharmaceutical Company and Idenix Pharmaceutical, Inc.

While with these organizations, he built two biometrics departments from the ground up, re-organized one department for effectiveness and productivity, and filed 15 new drug applications (NDAs) and supplemental NDAs with the U.S. Food & Drug Administration. The last NDA was filed under the new regulatory standard in electronic common technical document (eCTD).

Throughout his career, Dr. Chao has introduced state-of-the-art technologies to biometrics and clinical departments, including a CRF imaging and workflow, a data management system, a standard summary table generator, a clinical tracking system and an electronic data capture system.

Dr. Chao has worked in various therapeutic areas, including cardiovascular, oncology, HIV, hepatitis, neurology, radio-pharmacology and critical care medicine, and has met with the various regulatory agencies in the world, such as the FDA, EMA, KIKO, and SDA, on study design and NDA submission issues.

Dr. Chao was born in China and moved to Taiwan as a child. He obtained his B.S. degree in Agricultural Engineering from National Taiwan University and Ph.D. in Statistics from North Carolina State University at Raleigh.

Kevin B. Donovan
Vice President, Human Resources

Kevin B. Donovan is Vice President, Human Resources at Otsuka Pharmaceutical Development & Commercialization, Inc., where he oversees all human resources functions and delivers business outcomes through the creation and implementation of innovative HR strategies.

Before joining Otsuka in 2009, Mr. Donovan was Director, Human Resources, U.S. Field Sales, at AstraZeneca, where he led HR activities supporting a sales force of approximately 6,000 people. At AstraZeneca, he also held positions of Director, Global Human Resources Strategy in London and Director, Human Resources, U.S. Operations. Before that, Mr. Donovan spent eight years at Bristol-Myers Squibb and DuPont Pharmaceuticals Co., which was acquired by BMS.

Mr. Donovan received a Master’s degree in Organization Dynamics from the University of Pennsylvania and a Bachelor’s degree from the University of Delaware. He currently serves as an adjunct professor at Wilmington College.

Isaac W. Hammond, M.D., Ph.D.
Vice President, Clinical Drug Safety & Pharmacovigilance

Isaac W. Hammond is Vice President, Clinical Safety and Pharmacovigilance at Otsuka Pharmaceutical Development and Commercialization, Inc., where he oversees proactive safety and pharmacovigilance initiatives for all products in clinical development and all marketed products in the United States.

Before joining Otsuka, Dr. Hammond served as a Vice President and head of the Oncology Safety Evaluation and Risk Management team at GlaxoSmithKline, where he had global responsibility for the safety of all oncology products. He also served as a Medical Director at AstraZeneca with global safety responsibility for the development and registration of Crestor® (rosuvastatin calcium).

Earlier in his career, Dr. Hammond worked as a research scientist and physician at Eli Lilly & Co. He also was employed as a Medical Reviewer at the Food and Drug Administration in the Division of Cardiovascular and Renal Drugs Evaluations.

Dr. Hammond maintains adjunct teaching positions at the University of North Texas, Health Sciences Center at Fort Worth and at Texas A&M University, Health Sciences Center. He is a guest lecturer at the University of the Sciences in Philadelphia.

Prior to joining the pharmaceutical industry, Dr. Hammond was an Associate Professor of Epidemiology and Assistant Professor of Medicine at Tulane University Medical Center. He received a Bachelor of Science degree from California State University in Northridge and a Master’s degree in Public Health from Indiana University in Bloomington. He received a Ph.D. in Epidemiology & Biostatistics from Oklahoma University Medical Center and an M.D. from the University of Florida in Gainesville. He completed his residency in Internal Medicine at Emory University Medical Center in 1992.

Robert McQuade, PhD
Senior Vice President, Global Medical Affairs

Robert McQuade has over 25 years of pharmaceutical experience in the discovery, development and marketing of drugs for the treatment of mental illness.  He began his career as a post-doctoral fellow at Schering-Plough Pharmaceuticals in Central Nervous System (CNS) research.  He advanced through a number of positions, culminating in his role as Associate Director of CNS Pharmacology, where he supervised the CNS Pharmacology department, including the biochemistry/molecular biology and in vivo behavioral sections.  His research focus included Alzheimer's Disease, migraine, schizophrenia, and obesity.

Subsequently, he joined Bristol-Myers Squibb Co. in the department of Global Medical Affairs.  During his BMS tenure, Dr. McQuade was responsible for various products in the Global Medical Affairs department including psychiatric products for the treatment of generalized anxiety disorder and major depressive disorder.  He was also extensively involved in the Neuroscience Licensing Team that was responsible for identifying and finalizing the aripiprazole alliance agreement with Otsuka Pharmaceutical Company.  He was promoted to the position of Senior Director, Neuroscience Global Medical Affairs, and led the medical affairs team responsible for the Otsuka collaboration and the development, approval and launch of Abilify® (aripiprazole) in the U.S. and EU.

Dr. McQuade joined Otsuka in 2004, where he was initially responsible for global medical affairs for aripiprazole, as well as for compounds in late-stage development in the cardiovascular and gastrointestinal areas and CNS and oncology treatments.  Subsequently, with the formation of Otsuka Pharmaceutical Development & Commercialization, Inc., he assumed responsibility for Medical Affairs across the OPDC portfolio of development products.  In addition, he has been actively involved with in-licensing opportunities and with other external collaborations.  In 2008, he led the team responsible for the successful FDA advisory committee review of tolvaptan for the treatment of hyponatremia and was promoted to Senior Vice President, Global Medical and Regulatory Affairs.  Samsca® (tolvaptan) was approved in 2009 for the treatment of clinically significant hyponatremia by the FDA.

Dr. McQuade received his Bachelor of Science degree from Davidson College (Davidson, NC) and his Doctorate from the University of North Carolina (Chapel Hill, NC).  He has been a co-author of over 70 peer-reviewed publications and numerous abstracts and presentations.